Total Payments
$13,254
2024 Payments
$800.01
Companies
31
Transactions
251
Medicare Patients
1,727
Medicare Billing
$438,406
Payment Breakdown by Category
Food & Beverage$7,212 (54.4%)
Research$5,800 (43.8%)
Other$200.00 (1.5%)
Education$41.24 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,212 | 245 | 54.4% |
| Unspecified | $5,800 | 1 | 43.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $200.00 | 1 | 1.5% |
| Education | $41.24 | 4 | 0.3% |
Payments by Type
General
$7,454
250 transactions
Research
$5,800
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Keryx Biopharmaceuticals, Inc. | $5,904 | 6 | $0 (2018) |
| Amgen Inc. | $1,075 | 27 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $1,012 | 27 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $813.04 | 30 | $0 (2023) |
| Otsuka America Pharmaceutical, Inc. | $740.76 | 50 | $0 (2023) |
| Aurinia Pharma U.S., Inc. | $691.41 | 13 | $0 (2024) |
| Vifor Pharma, Inc. | $690.31 | 11 | $0 (2023) |
| Mallinckrodt Hospital Products Inc. | $273.77 | 7 | $0 (2024) |
| Novo Nordisk Inc | $254.22 | 3 | $0 (2024) |
| Fresenius USA Marketing, Inc. | $247.90 | 10 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $800.01 | 10 | Novo Nordisk Inc ($254.22) |
| 2023 | $1,673 | 45 | Bayer Healthcare Pharmaceuticals Inc. ($354.92) |
| 2022 | $1,143 | 37 | Bayer HealthCare Pharmaceuticals Inc. ($336.52) |
| 2021 | $825.53 | 15 | Vifor Pharma, Inc. ($316.82) |
| 2020 | $611.73 | 19 | Amgen Inc. ($380.22) |
| 2019 | $981.87 | 45 | Amgen Inc. ($254.73) |
| 2018 | $798.94 | 48 | Otsuka America Pharmaceutical, Inc. ($258.39) |
| 2017 | $6,420 | 32 | Keryx Biopharmaceuticals, Inc. ($5,868) |
All Payment Transactions
251 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/22/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $119.77 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 08/22/2024 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $101.79 | General |
| Category: CRITICAL CARE | ||||||
| 07/30/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $121.86 | General |
| 07/18/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $109.80 | General |
| 07/09/2024 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $16.07 | General |
| Category: CRITICAL CARE | ||||||
| 05/31/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $126.44 | General |
| Category: Cardio-renal | ||||||
| 05/21/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $22.56 | General |
| Category: Diabetes | ||||||
| 05/15/2024 | Amgen Inc. | Aranesp (Biological), Parsabiv, TAVNEOS | Food and Beverage | In-kind items and services | $24.72 | General |
| Category: Nephrology | ||||||
| 03/27/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $33.15 | General |
| Category: Cardio-renal | ||||||
| 03/14/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $123.85 | General |
| Category: Inflammation | ||||||
| 12/13/2023 | GlaxoSmithKline, LLC. | JESDUVROQ (Drug), BENLYSTA | Food and Beverage | In-kind items and services | $21.01 | General |
| Category: NEPHROLOGY | ||||||
| 12/06/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $19.49 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/30/2023 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $31.91 | General |
| 11/30/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $23.29 | General |
| Category: Cardio-renal | ||||||
| 11/30/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $23.23 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/28/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $23.16 | General |
| Category: DIABETES | ||||||
| 11/16/2023 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $16.44 | General |
| Category: Hyperkalemia | ||||||
| 11/09/2023 | Calliditas Therapeutics US Inc. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $138.90 | General |
| Category: Nephrology | ||||||
| 11/07/2023 | GlaxoSmithKline, LLC. | JESDUVROQ (Drug) | Food and Beverage | In-kind items and services | $80.51 | General |
| Category: NEPHROLOGY | ||||||
| 11/01/2023 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $26.61 | General |
| Category: NEPHROLOGY | ||||||
| 10/26/2023 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $22.71 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/19/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $23.35 | General |
| Category: KRYSTEXXA | ||||||
| 10/19/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $17.51 | General |
| Category: KRYSTEXXA | ||||||
| 10/06/2023 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $105.51 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 10/04/2023 | Fresenius USA Marketing, Inc. | — | Food and Beverage | In-kind items and services | $18.06 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Compass | Keryx Biopharmaceuticals, Inc. | $5,800 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 292 | 640 | $407,250 | $94,982 |
| 2022 | 9 | 459 | 855 | $370,360 | $96,512 |
| 2021 | 10 | 473 | 997 | $439,975 | $114,334 |
| 2020 | 8 | 503 | 1,103 | $634,160 | $132,578 |
Total Patients
1,727
Total Services
3,595
Medicare Billing
$438,406
Procedure Codes
33
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 22 | 143 | $257,400 | $40,659 | 15.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 123 | 273 | $50,505 | $25,906 | 51.3% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 20 | 50 | $60,000 | $11,749 | 19.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 57 | 61 | $21,655 | $8,229 | 38.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 24 | 50 | $9,500 | $4,712 | 49.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 46 | 63 | $8,190 | $3,728 | 45.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 176 | 383 | $70,855 | $30,664 | 43.3% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 22 | 100 | $180,000 | $28,945 | 16.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 75 | 77 | $27,375 | $11,059 | 40.4% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 21 | 43 | $51,600 | $10,344 | 20.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 74 | 120 | $15,600 | $6,546 | 42.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 35 | 64 | $12,160 | $5,454 | 44.8% |
| 90945 | Dialysis procedure including 1 evaluation | Facility | 2022 | 13 | 23 | $5,750 | $1,542 | 26.8% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 25 | 27 | $5,670 | $1,461 | 25.8% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 18 | 18 | $1,350 | $497.25 | 36.8% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 22 | 129 | $232,200 | $37,434 | 16.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 151 | 408 | $75,480 | $33,769 | 44.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 98 | 108 | $38,340 | $16,943 | 44.2% |
| 90961 | Dialysis services (2-3 physician visits per month), patient 20 years of age and older | Office | 2021 | 21 | 42 | $50,400 | $10,068 | 20.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 88 | 124 | $16,120 | $7,088 | 44.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 30 | 56 | $10,640 | $4,805 | 45.2% |
| 90935 | Hemodialysis procedure with one physician evaluation | Facility | 2021 | 24 | 31 | $6,510 | $1,833 | 28.2% |
| 90945 | Dialysis procedure including one evaluation | Facility | 2021 | 14 | 22 | $5,500 | $1,552 | 28.2% |
| 90970 | Dialysis services, per day (less than full month service), patient 20 years of age or older | Office | 2021 | 14 | 66 | $3,960 | $524.00 | 13.2% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 11 | 11 | $825.00 | $317.14 | 38.4% |
About Dr. Judith Betts, MD
Dr. Judith Betts, MD is a Nephrology healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1992735120.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Judith Betts, MD has received a total of $13,254 in payments from pharmaceutical and medical device companies, with $800.01 received in 2024. These payments were reported across 251 transactions from 31 companies. The most common payment nature is "Food and Beverage" ($7,212).
As a Medicare-enrolled provider, Betts has provided services to 1,727 Medicare beneficiaries, totaling 3,595 services with total Medicare billing of $438,406. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Austin, TX
- Active Since 07/04/2006
- Last Updated 07/21/2023
- Taxonomy Code 207RN0300X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1992735120
Products in Payments
- Auryxia (Drug) $5,946
- Kerendia (Drug) $1,012
- Veltassa (Drug) $737.69
- LUPKYNIS (Drug) $691.41
- SAMSCA (Drug) $502.44
- FARXIGA (Drug) $450.74
- Parsabiv (Biological) $431.29
- Parsabiv (Drug) $380.22
- LOKELMA (Drug) $362.30
- ACTHAR (Biological) $252.61
- JYNARQUE (Drug) $238.32
- Velphoro (Drug) $206.15
- INJECTAFER (Drug) $202.41
- TAVNEOS (Drug) $158.15
- TARPEYO (Drug) $138.90
- TERLIVAZ (Drug) $117.86
- JESDUVROQ (Drug) $101.52
- ENTRESTO (Drug) $93.25
- Rituxan (Biological) $81.31
- Sensipar (Drug) $80.27
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Austin
Harry Goss, Md, MD
Nephrology — Payments: $215,488
Nephrology $215,488
Dr. Michelle Lubetzky, Md, MD
Nephrology — Payments: $33,694
Nephrology $33,694
Margaret Cook, Md, MD
Nephrology — Payments: $10,676
Nephrology $10,676
Vincent Tjia, Md, MD
Nephrology — Payments: $7,190
Nephrology $7,190
Dr. Andrew Pelphrey, M.d, M.D
Nephrology — Payments: $6,428
Nephrology $6,428
Sujatha Venkatesh, Md, MD
Nephrology — Payments: $5,559
Nephrology $5,559